查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1450288

中性粒细胞减少症市场：现况分析与预测（2023-2030）

Neutropenia Market: Current Analysis and Forecast (2023-2030)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 152 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计 2023 年至 2030 年中性粒细胞减少症市场的复合年增长率约为 5.5%。 中性粒细胞减少症是一种以中性粒细胞数量减少为特征的疾病，中性粒细胞是免疫系统必需的白血球类型。 中性粒细胞减少症可由多种原因引起，包括化疗、某些药物和潜在的医疗状况。 中性粒细胞减少症市场包括旨在解决中性粒细胞减少症和改善患者预后的药物介入、治疗方法、诊断工具和支持性护理。 癌症治疗（尤其是化疗）引起的中性粒细胞减少症盛行率不断增加，正在推动市场发展。 癌症患者经常会出现中性粒细胞减少症的副作用，这增加了对治疗干预措施的需求，以管理和预防相关併发症。 例如，根据泛美卫生组织估计，2023年，全球将新增2,000万癌症病例，1,000万人因癌症死亡。 未来 20 年，癌症负担将增加约 60%，给卫生系统、人民和社区带来进一步的压力。

依类型划分，市场分为先天性嗜中性白血球减少症、发烧性嗜中性白血球减少症、週期性嗜中性白血球减少症、自体免疫性嗜中性白血球减少症等。 其中，发烧性嗜中性白血球减少症市场的复合年增长率较高，因为它与感染的脆弱性增加有关，特别是在接受化疗等癌症治疗的人群中，预计该市场将会成长。 当癌症患者出现发烧且嗜中性球计数较低（中性粒细胞减少症）时，就会出现发烧性疾病，通常表示有潜在感染。 发烧性嗜中性白血球减少症会带来严重感染的重大风险，如果没有快速有效地处理，可能会导致危及生命的併发症。

依治疗方式，市场分为抗生素治疗、集落刺激因子治疗、粒细胞输注等。 其中，集落刺激因子治疗领域预计将以较高的复合年增长率成长。 集落刺激因子（CSF）治疗领域在中性粒细胞减少症市场中非常重要，因为它在治疗中性粒细胞减少症方面发挥关键作用。 中性粒细胞减少症通常是癌症治疗的副作用，脑脊髓液治疗透过刺激嗜中性球（一种白血球）的产生来帮助降低感染风险。 由于化疗引起的中性粒细胞减少症的盛行率不断增加以及对有效支持治疗的需求，该领域正在经历增长。

依最终使用者划分，市场分为医院、家庭护理、专科中心等。 其中，医院类别预计在预测期内中性粒细胞减少症招募量将增加。 由于癌症发生率不断上升以及广大民众对癌症的认识不断提高，到医院就诊和治疗的患者数量不断增加。 中性粒细胞减少症市场的医院部分被认为是关键的成长因素。 医院在中性粒细胞减少症的诊断、治疗和管理中发挥核心作用，特别是在需要密切监测、专门护理和干预的严重病例中。 此外，严重的中性粒细胞减少症，尤其是伴随发烧的中性粒细胞减少症，可能需要住院治疗。 医院提供住院服务，患者接受重症监护、持续监测以及出现併发症时的快速介入。

为了更了解中性粒细胞减少症产业的市场实施情况，我们根据其在北美、欧洲、亚太地区和世界其他地区的全球影响力对市场进行了分析。 北美中性粒细胞减少症市场的推动因素包括癌症发病率上升、医疗保健专业人员和普通大众对中性粒细胞减少症的认识不断增强、先进成像技术的市场发展以及治疗选择数量的增加。预计该市场将在未来继续增长。未来。 例如，根据美国癌症协会的数据，2020 年，癌症是美国仅次于心臟病的第二大死因。 预计 2022 年美国将有约 609,360 人死于癌症，相当于每天约 1,670 人死亡。

参与市场的主要公司包括辉瑞公司、诺华公司、阿斯特捷利康公司、梯瓦製药工业有限公司、迈兰公司、赛诺菲公司、葛兰素史克公司、默克公司、西普拉公司、希根公司等。

目录

第1章市场介绍

  • 市场定义
  • 主要目标
  • 利害关係人
  • 限制

第2章研究方法或前提

  • 调查过程
  • 调查方法
  • 受访者简介

第3章市场总结

第 4 章执行摘要

第 5 章 COVID-19 对嗜中性白血球减少症市场的影响

第 6 章全球嗜中性白血球减少症市场收入（2020-2030 年）

第 7 章市场洞察：按类型

  • 先天性嗜中性白血球减少症
  • 发烧中性白血球减少症
  • 循环中性白血球减少症
  • 自体免疫性嗜中性白血球减少症
  • 其他

第 8 章市场洞察：依治疗方法

  • 抗生素治疗
  • 集落刺激因子疗法
  • 粒细胞输注
  • 其他

第 9 章市场洞察：最终用户

  • 医院
  • 居家护理
  • 专业中心
  • 其他

第 10 章市场洞察：按地区

  • 北美
    • 美国
    • 加拿大
    • 北美其他地区
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 亚太地区其他地区
  • 世界其他地区

第 11 章中性白血球减少症市场动态

  • 市场驱动因素
  • 市场挑战
  • 影响分析

第 12 章中性白血球减少症市场机会

第 13 章中性白血球减少症市场趋势与见解

第14章需求面与供给面分析

  • 需求方分析
  • 供给面分析

第 15 章价值链分析

第16章价格分析

第17章竞争场景

  • 竞争状况
    • 波特五力分析

第18章公司简介

  • Pfizer Inc.
  • Novartis AG
  • AstraZeneca
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V
  • Sanofi
  • GSK plc
  • Merck & Co., Inc
  • Cipla Inc
  • Seagen, Inc

第19章 免责事项

简介目录
Product Code: UMHE212622

The Neutropenia market is expected to register a CAGR of approx. 5.5% over the period of 2023-2030. The Neutropenia is a medical condition characterized by a low count of neutrophils; a type of white blood cell essential for the immune system. Neutropenia can result from various causes, including chemotherapy, certain medications, or underlying medical conditions. The market encompasses pharmaceutical interventions, therapeutic approaches, diagnostic tools, and supportive care aimed at addressing neutropenia and improving patient outcomes. The Growing prevalence of neutropenia induced by cancer treatments, particularly chemotherapy is boosting the neutropenia market. Cancer patients often experience neutropenia as a side effect, increasing the demand for therapeutic interventions to manage and prevent associated complications. For instance, according to PAHO, in 2023, Globally, there were an estimated 20 million new cases of cancer and 10 million deaths from cancer. The cancer burden will increase by approximately 60% over the next two decades, further straining health systems, people and communities.

Based on the type, the market has been categorized into congenital neutropenia, febrile neutropenia, cyclic neutropenia, autoimmune neutropenia and others. Among them, the febrile neutropenia segment is expected to grow at a higher CAGR in the market due to its association with increased vulnerability to infections, especially among individuals undergoing cancer treatments such as chemotherapy. Febrile neutropenia occurs when cancer patients with a low neutrophil count (neutropenia) develop a fever, which is often indicative of an underlying infection. Febrile neutropenia poses a significant risk of severe infections, and if not managed promptly and effectively, it can lead to life-threatening complications.

Based on the treatment, the market has been categorized into antibiotic therapy, colony-stimulating factor therapy, granulocyte transfusion, and others. Among them, the colony-stimulating factor therapy segment is expected to grow at a higher CAGR in the market. The colony-stimulating factor (CSF) therapy segment is crucial in the Neutropenia market because it plays a key role in managing neutropenia, particularly in cases where the condition is induced by chemotherapy or other medical treatments. Neutropenia is often a side effect of cancer treatments, and CSF therapy helps stimulate the production of neutrophils, a type of white blood cell, to reduce the risk of infections. This segment has witnessed growth due to the increasing prevalence of chemotherapy-induced neutropenia and the need for effective supportive care.

Based on the end-user, the market has been categorized into Hospitals, Homecare ,Speciality Centres, and Others. Among them, the hospital category is to witness higher adoption of Neutropenia during the forecast period. The rising incidence of cancer and the growing awareness of cancer among the general population has led to an increased number of patients seeking medical attention and Type at hospitals. The hospital segment in the Neutropenia market is considered a crucial and growing component. Hospitals play a central role in the diagnosis, treatment, and management of neutropenia, particularly in severe cases where close monitoring, specialized care, and interventions are necessary. Moreover, Severe neutropenia, especially cases involving febrile neutropenia, may require hospitalization. Hospitals offer inpatient services where patients can receive intensive care, continuous monitoring, and prompt intervention in case of complications.

For a better understanding of the market adoption of the Neutropenia industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The North America neutropenia market is expected to continue to grow in the coming years, driven by the increasing prevalence of cancer and growing awareness of neutropenia among healthcare professionals and the general population, development of advanced imaging techniques and the rise in treatment option. For instance, in 2020, according to American Cancer Society, Cancer is the second most common cause of death in the US, exceeded only by heart disease. around 609,360 deaths from cancer are expected in the US in 2022, which is about 1,670 deaths per day.

Some of the major players operating in the market include Pfizer Inc., Novartis AG, AstraZeneca, Teva Pharmaceutical Industries Ltd., Mylan N.V, Sanofi , GSK plc , Merck & Co., Inc, Cipla Inc, Seagen, Inc.

TABLE OF CONTENTS

1. MARKET INTRODUCTION

  • 1.1.Market Definitions
  • 1.2.Main Objective
  • 1.3.Stakeholders
  • 1.4.Limitation

2. RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1.Research Process of the Neutropenia Market
  • 2.2.Research Methodology of the Neutropenia Market
  • 2.4.Respondent Profile

3. MARKET SYNOPSIS

4. EXECUTIVE SUMMARY

5. IMPACT OF COVID-19 ON THE NEUTROPENIA MARKET

6. GLOBAL NEUTROPENIA MARKET REVENUE, 2020-2030F

7. MARKET INSIGHTS BY TYPE

  • 7.1.Congenital Neutropenia
  • 7.2.Febrile Neutropenia
  • 7.3.Cyclic Neutropenia
  • 7.4.Autoimmune Neutropenia
  • 7.5.Others

8. MARKET INSIGHTS BY TREATMENT

  • 8.1.Antibiotic Therapy
  • 8.2.Colony-Stimulating Factor Therapy
  • 8.3.Granulocyte Transfusion
  • 8.4.Others

9. MARKET INSIGHTS BY END-USERS

  • 9.1.Hospitals
  • 9.2.Homecare
  • 9.3.Speciality Centres
  • 9.4.Others

10. MARKET INSIGHTS BY REGION

  • 10.1NORTH AMERICA NEUTROPENIA MARKET
    • 10.1.1.U.S.
    • 10.1.2.Canada
    • 10.1.3.Rest of North America
  • 10.2EUROPE NEUTROPENIA MARKET
    • 10.2.1.Germany
    • 10.2.2.U.K.
    • 10.2.3.France
    • 10.2.4.Italy
    • 10.2.5.Spain
    • 10.2.6.Rest of Europe
  • 10.3ASIA PACIFIC NEUTROPENIA MARKET
    • 10.3.1.China
    • 10.3.2.Japan
    • 10.3.3.India
    • 10.3.4.Rest of Asia-Pacific
  • 10.4REST OF THE WORLD NEUTROPENIA MARKET

11. NEUTROPENIA MARKET DYNAMICS

  • 11.1.Market Drivers
  • 11.2.Market Challenges
  • 11.3.Impact Analysis

12. NEUTROPENIA MARKET OPPORTUNITIES

13. NEUTROPENIA MARKET TRENDS & INSIGHTS

14. DEMAND AND SUPPLY SIDE ANALYSIS

  • 14.1.Demand Side Analysis
  • 14.2.Supply Side Analysis

15. VALUE CHAIN ANALYSIS

16. PRICING ANALYSIS

17. COMPETITIVE SCENARIO

  • 17.1.Competitive Landscape
    • 17.1.1Porter's Five forces analysis

18. COMPANY PROFILED

  • 18.1.Pfizer Inc.
  • 18.2.Novartis AG
  • 18.3.AstraZeneca
  • 18.4.Teva Pharmaceutical Industries Ltd.
  • 18.5.Mylan N.V
  • 18.6.Sanofi
  • 18.7.GSK plc
  • 18.8.Merck & Co., Inc
  • 18.9.Cipla Inc
  • 18.10.Seagen, Inc

19. DISCLAIMER